hydroxychloroquine

P4, N=58, Completed, Guizhou Provincial People's Hospital (Single center research); Guizhou Provincial People's Hospital

P4, N=585, Not yet recruiting, Christian Medical College, Vellore, India

P2, N=300, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Apr 2025

Our findings demonstrate that upregulation of LYPLAL1-DT sequesters apoptosis through the LYPLAL1-DT/miR-204-5p/BCL2 axis and promotes autophagy by facilitating the assembly of the BECN1/PtdIns3K complex, thereby mediating multi-drug resistance of SCLC. The triple combination of venetoclax, HCQ, in conjunction with cDDP, VP-16 or PTX overcomes refractory SCLC, shedding light on a potential therapeutic target for combating SCLC chemoresistance.

P1/2, N=8, Terminated, University of Michigan | N=12 --> 8 | Trial completion date: Jan 2026 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2024; Unable to recruit additional participants after multiple extensions to planned enrollment period.

The findings from this study offered robust evidence supporting the use of hydroxychloroquine as a treatment for non-small cell lung cancer (NSCLC). Consequently, hydroxychloroquine emerges as a potential therapeutic agent for the treatment of this cancer.

P=N/A, N=796, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P4, N=1000, Recruiting, Liverpool School of Tropical Medicine | Not yet recruiting --> Recruiting

P4, N=78, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Dec 2024

P2, N=19, Active, not recruiting, HonorHealth Research Institute | Trial completion date: Sep 2024 --> Dec 2024

She was diagnosed with rheumatoid arthritis with Castleman like histopathology in lymph nodes and was treated with methotrexate and hydroxychloroquine sulfate combined with glucocorticoids. In the first year after sur-gery, the patient' s condition remained stable and there was no growth of lymph nodes in the right axilla. The patient passed away due to severe infection in the second year after the surgery.

P2/3, N=200, Recruiting, Tongji Hospital | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2024 --> Sep 2024

THCQ and TP are not effective in patients with advanced PDAC harboring KRAS mutations or alterations in MAPK/CDKN2A/B.

We evaluated the association of treatment outcomes in a Phase 2 trial of neoadjuvant nab-paclitaxel (A), gemcitabine (G), cisplatin (C), and paricalcitol (P) (NCT03138720) and a Phase 2 trial of A+G+C+hydroxychloroquine (HCQ) (NCT04669197) in patients with non-metastatic PDAC. In the study of A+G+C+P, there was a disparity in OS between patients with basal-like vs. classical tumors, in contrast to the interim results of the COMPASS and PASS-01 trials, where patients with basal-like tumors receiving A+G had similar OS compared to patients with classical tumors. Compared to prior analysis, there was no difference in OS for patients with permCAF tumors vs.

P2, N=22, Recruiting, Cancer Trials Ireland | Trial completion date: Apr 2025 --> Jun 2026 | Trial primary completion date: Jul 2024 --> Sep 2025

P2/3, N=10, Terminated, Columbia University | N=1600 --> 10 | Recruiting --> Terminated; The Institutional Review Board closed the study

P2, N=600, Active, not recruiting, ProgenaBiome | Recruiting --> Active, not recruiting | Phase classification: P2a --> P2 | Trial completion date: Jul 2025 --> Dec 2024

Drug-induced lupus is a clinical syndrome that shares similar features with systemic lupus erythematosus (SLE). The majority of patients present with symptoms such as arthralgia and myalgia. Hydralazine and procainamide are high-risk drugs for drug-induced lupus. Symptoms usually develop after months or years of use, but may also develop suddenly. Our patient also received TDM-1 treatment for 18 months. We present a case of TDM-1-associated drug-induced lupus in a patient with metastatic breast cancer. This is the first case of TDM-1-related drug-induced lupus reported in the literature.

Seven drugs were shortlisted for their time-dependent (10-12 days) cytotoxic effect and further narrowed to three effective drugs (e.g., cisplatin, doxorubicin, and hydroxychloroquine). We identified multiple druggable targets and, using ex-vivo methods narrowed multiple drugs to disease-condition-specific therapeutics. We consider that our investigation successfully interconnected the expression data with the functional disease-specific therapeutic investigation and selected drugs can be used for effective resistant treatment with higher therapeutic response.

P3, N=400, Recruiting, University of Nebraska | Trial primary completion date: Mar 2026 --> Mar 2027

P=N/A, N=188, Not yet recruiting, Dongzhimen Hospital, Beijing University of Chinese Medicine; Dongzhimen Hospital, Beijing University of Chinese Medicine

P=N/A, N=65, Terminated, University of California, San Francisco | Trial completion date: Feb 2025 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Feb 2024; Study investigators became aware of an internal error that overrode randomization of providers; therefore, the study randomization for this study was no longer present.

These findings support that HCQ plays a role in the treatment of mice colitis possibly by altering the gut microbiota.

In our study, both the MTX + HCQ combination therapy and MTX monotherapy demonstrated improvements in symptoms, conditions and quality of life for patients with RA. Notably, the combination therapy could achieve better outcomes across all indices compared to MTX monotherapy, highlighting its potential as the optimal first-line treatment for RA.

The autophagy inhibition of HFn@HCQ has been demonstrated, which is a major pathway to induce cancer cell death. According to current findings, HFn based drug delivery is a promising strategy to target and kill TfR1 overexpressing tumor cells.

P=N/A, N=50, Recruiting, University Hospital, Toulouse | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024

Simultaneously, in order to refrain from mitophagy, hydroxychloroquine is mixed with NBE to form a combo with strength pyroptosis. As a result, NBE/combo improves the PAFerroptosis obviously by activation of CD8+T cells and inactivation of MDSC cells, up-regulating expression of caspase-3 signal pathway, intercepting DHODH pathway to arrive excellent antitumor effect (93%). Therefore, this study establishes a rational nanoenzyme for mitochondrial dysfunction without mitophagy for effective antitumor therapy.

P1, N=20, Not yet recruiting, Lionel.D.Lewis, MD | Initiation date: Jun 2024 --> Sep 2024

P2, N=5, Terminated, ECOG-ACRIN Cancer Research Group | N=84 --> 5 | Trial completion date: Nov 2025 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Jan 2024; Slow accrual

P4, N=24, Terminated, Duke University | Active, not recruiting --> Terminated; Showed no benefit

P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025

After internalization and lysosomal escape, the nanoparticle disassembles in response to the reactive oxygen species (ROS), subsequently releasing the iron chelator Dp44mT and autophagy-inhibitory drug hydroxychloroquine (HCQ)...Consequentially, Dp44mT@HTH induces irreversible mitochondrial impairments, in this respect creating a substantial toxic stack state that induces apoptosis and cell death. Initiating from the perspective of endogenous substances, this strategy illuminates the promise of iron depletion therapy via irreversible mitochondrial damage induction for anticancer treatment.

P2, N=64, Active, not recruiting, The University of Texas Health Science Center at San Antonio | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2025

A hydroxychloroquine (HCQ) platinum(IV) complex with autophagy suppressing potency was developed, which displayed potent antitumor activities with a TGI rate of 44.2% against 4T1 tumors in vivo and exhibited a rather lower toxicity than cisplatin. Adaptive immune response was improved by inhibiting the immune checkpoint PD-L1 and further increasing CD4+ and CD8+ T cells in tumors. Then, tumor metastasis was effectively inhibited by restraining angiogenesis through inhibiting VEGFA, MMP-9, and CD34.

Then, the thermosensitive liposome modified with FAP-α-responsive peptide (CAP) was used as a carrier to encapsulate autophagy inhibitor hydroxychloroquine (HCQ) and Tf-Te, to obtain an intelligent TT@CH delivery system...Meanwhile, lung metastatic nodules of TT@CH treated mice reduced by 124.33 compared with that of mice in control group. Overall, TT@CH provided an effective therapy strategy for melanoma.

P2, N=334, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne | Initiation date: Jun 2024 --> Sep 2024

P=N/A, N=140, Recruiting, King's College Hospital NHS Trust | Not yet recruiting --> Recruiting | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026

CsA treatment might be helpful for certain patients with ABCA3 deficiency, however, currently strong clinical supporting evidence is lacking. Appropriate trials are necessary to overcome this unmet need.

P=N/A, N=56, Recruiting, Erasmus Medical Center

P=N/A, N=315, Completed, Erasmus Medical Center

P2, N=47, Terminated, BioMed Valley Discoveries, Inc | N=215 --> 47 | Trial completion date: Mar 2025 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> May 2024; Lack of Enrollment for Remaining Open Baskets

P4, N=43, Active, not recruiting, Guy's and St Thomas' NHS Foundation Trust | Recruiting --> Active, not recruiting | N=76 --> 43 | Trial primary completion date: Sep 2024 --> May 2025